Company
Convert Pharmaceuticals
- Biotech
- Location:
- Liege, Belgium
Description
Convert Pharmaceuticals develops hypoxia-activated prodrugs that remain inert on administration and convert into tumor-selective anti-cancer agents within the tumor microenvironment, using biomarker-driven selection and preclinical-to-clinical development activities.
Convert Pharmaceuticals is located in the Belgium ecosystem.
Related
OncomatryxOncomatryx targets the tumor microenvironment with stroma-focused antibody-drug conjugates, applying this approach to metastatic solid…
TILT BiotherapeuticsTILT Biotherapeutics develops oncolytic viral immunotherapies and engineered viral payloads to modify tumor microenvironments and enhance…
- CeraVxCeraVx develops ceramic CeraMaps microneedle patches for intradermal delivery of vaccines and medicines, using biocompatible, inert…
Herantis PharmaHerantis Pharma develops disease-modifying therapies designed to stop or reverse progression of neurodegenerative diseases, applying drug…
Relevium MedicalRelevium Medical develops injectable hydrogel, TRPV1-targeting prodrug therapeutics designed to ablate or modulate peripheral nervous…
CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…
BiosimulyticsBiosimulytics uses computational crystal structure prediction to map a molecule's solid-form landscape, predict competing polymorphs, and…
NeoPhoreNeoPhore develops small-molecule cancer therapeutics that briefly inhibit DNA mismatch repair, shifting MMR-proficient tumors toward an…
EurogentecEurogentec provides life-science products and CDMO manufacturing for research, diagnostics and therapeutics, producing oligonucleotides,…